What is the real situation without TH1902Analysts gave no value to TH1902 or the oncology program, but with the last news,the stock lost more than half of it's value. It seems excessive. Can somebody give us a summary of what is the financial situation of the company if we remove oncology and keep NASH only as a possibility without spending much on it?
In other words,what would be a fair value for the stock based only on the commercial business taking intoaccount the debt situation. My investment thesis was that oncology was a free bet because the company without it would still be worth enough to justify the 3-4$C stock price.
So what we see now could be just an overrecation amplified by the awful communication by the company. I don't want to be reassured, I just want to have the real picture of the situation.